Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

OBJECTIVES: To assess the long-term safety and efficacy of ixekizumab, an IL-17A antagonist, in patients with active PsA. METHODS: In SPIRIT-P2 (NCT02349295), patients (n = 363) with previous inadequate response to TNF inhibitors entered the double-blind period (weeks 0–24) and received placebo or i...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C, Combe, Benard, Kremer, Joel M, Tsai, Tsen-Fang, Behrens, Frank, Adams, David H, Lee, Chin, Kerr, Lisa, Nash, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199530/
https://www.ncbi.nlm.nih.gov/pubmed/30053162
http://dx.doi.org/10.1093/rheumatology/key182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199530/
https://www.ncbi.nlm.nih.gov/pubmed/30053162
http://dx.doi.org/10.1093/rheumatology/key182

Ejemplares similares